Shares of Mid-cap life sciences company Natera moved 16.93% this afternoon, and are now trading at $49.51 per share. On the other hand, the average analyst target price for the stock is $72.
Natera, Inc., a diagnostic company, develops and markets molecular testing services globally.
Natera investors should be aware of the below:
The company has a net profit margin of -70.3%, compared to its operating margins of -0.69%. Its Revenues have a year-on-year growth rate of 33.2%, compared to a YoY growth rate of 0.0% for its earnings.
Based on its trailing earning per share of -5.89, Natera has a trailing 12 month Price to Earnings (P/E) ratio of -8.41
Its Price to Book (P/B) ratio is 11.74
2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | |
---|---|---|---|---|---|
EPS | -$4.96 | -$2.66 | -$1.60 | -$2.06 | -$2.55 |
EPS Growth | -86.0% | -67.0% | 22.0% | 19.0% | n/a |
Shares Outstanding (k) | 95,140 | 86,223 | 78,005 | 62,082 | 54,040 |
Shares Growth | 10.0% | 11.0% | 26.0% | 15.0% | n/a |
Net Income (k) | -$471,700 | -$229,743 | -$124,827 | -$128,154 | -$137,628 |
Net Income Growth | -105.3% | -84.0% | 2.6% | 6.9% | n/a |